Knight Therapeutics, Inc. · TSX:GUD
Knight Therapeutics — Q1 2026 Earnings Presentation
25 slides from Knight Therapeutics's earnings presentation, May 7, 2026
Slide 1: Delivering Results, Transforming Lives
DELIVERING RESULTS TRANSFORMING LIVES KNIGHT THERAPEUTICS INC. TSX: GUD APRIL 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This document contains forward-looking statements and forward-looking information for Knight Therapeutics Inc. and its subsidiaries within the meaning of applicable Canadian securities laws. Forward-looking statements are subject to known and unknown risks, uncertainties a
Slide 3: Knight Overview
Knight Overview Building a Solid Foundation Since 2014 Focused on Acquiring or In-Licensing Innovative Pharmaceutical Products for Canada and Latin America 2019 $685M Acquisition of Grupo Biotoscana, June 2025 a specialty pharmaceutical Closed Paladin and Raised in equity company with presence acros
Slide 4: Scaling the Platform
Scaling the Platform By the Numbers $452M $73M $95M Adjusted Revenues in 2025 Adjusted EBITDA in 2025 Cash and Marketable Securities 24% Growth vs. 2024 26% Growth vs. 2024 $68M in Loans 16 agreements >$200M $240M signed for 65+ products Current Pipeline Syndicated Banking in past 5 years Expected R
Slide 5: Our Growth Strategies
Our Growth Strategies Knight’s involvement Regulatory Market Sales & Discovery Pre-Clinical Clinical Trials Approval Access Marketing 2 - 10 yrs 2 - 4 yrs 5 - 7 yrs 1 - 3 yrs 1 - 3 yrs 3 - 5 yrs 1 In-license late-stage prescription pharmaceuticals 2 Acquire mature or “under-promoted” products from B
Slide 6: Our Footprint
Our Footprint Growing Across Key Markets 2025 ADJUSTED REVENUE BY GEOGRAPHY $452M 11 Countries plus distributors in Central Other Other Adjusted Revenue America & Caribbean Mexico 4% Mexico 4% 5% Argentina 5% Argentina 8% 10% Brazil Rest of Brazil Rest of 40% LATAM 37% LATAM 8% FY-2025 Q4-2025 +150
Slide 7: Paladin & Sumitomo Transactions
Paladin & Sumitomo Transactions Adding over 45 Products and Over $80 million in Annual Sales PALADIN SUMITOMO • Asset purchase agreement to acquire Paladin • Agreements for: (i) Myfembree®, Orgovyx® and Gemtesa®, and (ii) • Purchase price of $93M + $23M for inventory, and potential an asset purchase
Slide 8: Our Markets – Sizable & Growing
Our Markets – Sizable & Growing Pan-American (ex US) represents ~6% of global pharma market MARKET SIZE AT CONSTANT CURRENCY $120 $100 $80 Larger market allows Knight to access more licensing $ Billions $60 and acquisition $40 92.1 96.0 opportunities. 74.3 62.1 50.4 47.7 $20 39.8 43.5 39.3 39.4 30.2
Slide 9: Our Portfolio
Our Portfolio Diversified and Growing ADJUSTED REVENUE BY THETRAPEUTIC AREA KEY PRODUCTS BY THETRAPEUTIC AREA Oncology & Hematology Other Specialty Oncology & 13% Hematology 33% Neurology 19% Infectious Disease $452M Adjusted Revenue Neurology Other Specialty Infectious Disease 36% Refer to the Foot
Slide 10: Our Partners
Our Partners Partner of Choice for Canada & Latin America 10
Slide 11: Moving Forward … A Proven Business Model
Moving Forward … A Proven Business Model Delivering Growth on Unique Platform Continuing to Demonstrate Excellent Growth Opportunity: Executed on 13 launches in 2024 and 2025 expected to achieve annual peak sales of $100 million Expect to have at least 10 launches in 2026 across Canada and Lat
Slide 12: Financial Highlights
Financial Highlights Revenue Growing in all Therapeutic Areas ADJUSTED REVENUE BY THERAPEUTIC AREA $500 $450 $400 $350 $300 Between $490 - $510M C$ Millions $250 $200 2026 Revenue Guidance $150 $100 $50 $0 2019 2020 2021 2022 2023 2024 2025 Oncology & Hematology Infectious Diseases Neurology Other S
Slide 13: Financial Highlights
Financial Highlights Strong Adjusted EBITDA and Cash Flow ADJUSTED EBITDA CASH FLOW FROM OPERATIONS $80 $80 $70 $70 $60 $60 $50 $50 C$ Millions $40 C$ Millions $40 $30 $30 $20 $20 $10 $0 $10 2019 2020 2021 2022 2023 2024 2025 -$10 $0 2019 2020 2021 2022 2023 2024 2025 -$20 ~15% Significant cash gene
Slide 14: Balance Sheet Highlights (Dec 31, 2025)
Balance Sheet Highlights (Dec 31, 2025) Healthy Balance Sheet with Capacity for More Acquisitions $95.3M $98.4M $67.9M Cash and Marketable Securities Financial Assets Debt $0.97/share $1.00/share $0.69/share 0.93 x 0.36:1 Credit Available Debt to TTM Debt to Equity Line of Credits: $105M Adjusted EB
Slide 15: Capital Allocation
Capital Allocation Executing on Acquisitions and NCIB PRODUCTS & ACQUISITIONS SHARE BUYBACK $250 $70 $60 $200 $50 $150 C$ Millions C$ Millions $40 $30 $100 $20 $50 $10 $0 $0 2019 2020 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2024 2025 Knight Knight acquires Over $250M invested in NCIB acqui
Slide 16: Capital Structure
Capital Structure As at March 13, 2026 $598M 98.0M 23.2% Market Capitalization Common Shares Outstanding Insider Holdings % $472M $73M 6.9M Adjusted Enterprise Value Adjusted EBITDA in 2025 Stock Options and Share Awards Refer to the Footnotes & Glossary slide for definitions of non-GAAP measures. 1
Slide 17: Management Team
Management Team Executing on Growth & Performance Monica Percario - Brazil Global VP Regulatory and Quality Samira Sakhia - Canada Sanofi, Head of Regulatory and Center of Expertise LATAM President and Chief Executive Officer Farmasa (now Hypera Pharma), Regulatory Affairs Paladin Labs, Chief Financ
Slide 18: Board Members
Board Members Proven Track Record Jonathan Ross Goodman Robert N. Lande Executive Chairman Paladin Labs, Board member from 1995 to 2014 Knight Therapeutics, Founder Stratos Global International LLC, President Paladin Labs, Co-founder, former President & CEO Michael J. Tremblay Former President of As
Slide 19: Knight’s Future Growth
Knight’s Future Growth Keep Growing, Keep Adding Add new Grow products to existing the products portfolio Deliver on new launches and pipeline 19
Slide 20: Key Achievements – in just the last 2 years
Key Achievements – in just the last 2 years Going from Pipeline to Growth 50+ New Products • Added Paladin assets - 40+ products • Added Sumitomo assets - 6 products • Crexont® • Onicit® Launches • Three branded generic products • Minjuvi® - DLBCL • Zynyz® Submissions • Tavalisse® • Imvexxy® & Bijuv
Slide 21: Why Knight – Great Value in Growing Markets
Why Knight – Great Value in Growing Markets The only scaled specialty pharma platform spanning Canada and Latin America Experienced Management Team – proven track record! Strong revenue growth potential via recent acquisitions and product launches Significant pipeline opportunities - over $2
Slide 22: Footnotes & Glossary
Footnotes & Glossary (1) Adjusted Revenue, financial results at constant currency, Adjusted EBITDA, and Adjusted EBITDA per share are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by o
Slide 23: Delivering Results, Transforming Lives
DELIVERING RESULTS TRANSFORMING LIVES KNIGHT THERAPEUTICS INC. TSX: GUD APRIL 2026
Slide 24: Our Portfolio
Our Portfolio Diversified and Growing ADJUSTED REVENUE BY PORTFOLIO BGx Innovative 11% The Innovative portfolio consists of the pharmaceutical products with innovative molecules and includes both in-licensed products such as Lenvima®, Cresemba®, Halaven®, Trelstar®, Akynzeo®, Ambisome®, Minjuvi®, Im
Slide 25: Strategic Fund Investments
Strategic Fund Investments Delivery Healthy Returns and Cash FUND PERFORMANCE1 FMV of Funds by expected exit date as at December 31, 2025 $1 1-3 years 61.7 4-5 years 17.5 5+ years 0.3 Total 79.5 1 In millions of dollars 2 Represents total value to paid-in ratio which is calculated as distributions r